April 21 (Reuters) - Corcept Therapeutics Inc CORT.O:
DIABETES CARE PUBLISHES RESULTS FROM PREVALENCE PHASE OF CORCEPT’S CATALYST TRIAL IN PEOPLE WITH DIFFICULT-TO-CONTROL TYPE 2 DIABETES
Source text: ID:nBw3rV971a
Further company coverage: CORT.O
((Reuters.Briefs@thomsonreuters.com;))